Products
2660 products
Code | Description | Unit |
---|---|---|
EPY0001366 | Torasemide impurity E - ethyl [[4-[(3-methylphenyl)amino]pyridin-3-yl]sulfonyl]carbamate | EP unit |
EPY0001367 | Cefprozil for peak identification | EP unit |
EPY0001368 | Cefprozil impurity mixture | EP unit |
EPY0001369 | Macrogol 30 dipolyhydroxystearate | EP unit |
EPY0001370 | Olanzapine | EP unit |
EPY0001371 | Cefprozil | EP unit |
EPY0001372 | Cefprozil impurity A - (2R)-2-amino-2-(4-hydroxyphenyl)acetic acid (p-hydroxyphenylglycine) | EP unit |
EPY0001373 | Nicergoline | EP unit |
EPY0001374 | Racemic methyldopa | EP unit |
EPY0001376 | 2-Methylpyrazine | EP unit |
EPY0001377 | Nitrofural for peak identification | EP unit |
EPY0001378 | Naringin | EP unit |
EPY0001379 | Levonorgestrel impurity B - 13-ethyl-17-hydroxy-18,19-dinor-17-alpha-pregn-5(10)-en-20-yn-3-one | EP unit |
EPY0001380 | Olanzapine for system sitability | EP unit |
EPY0001381 | Glucosamine for system suitability | EP unit |
EPY0001382 | Levothyroxine for peak identification | EP unit |
EPY0001383 | Homatropine methylbromide for system suitability | EP unit |
EPY0001384 | Fusidic acid impurity mixture | EP unit |
EPY0001385 | Angelica pubescent root | EP unit |
EPY0001386 | Angelica dahuria root | EP unit |
EPY0001387 | Candesartan for peak identification | EP unit |
EPY0001388 | Candesartan cilexetil | EP unit |
EPY0001389 | Candesartan for system suitability | EP unit |
EPY0001390 | Cyproterone acetate for peak identification | EP unit |
EPY0001391 | Glycerol formal | EP unit |
EPY0001392 | Olanzapine impurity A - 5-methyl-2-[(2-nitrophenyl)amino]thiophene-3-carbonitrile | EP unit |
EPY0001393 | Lincomycin chlorhydrate for system suitability | EP unit |
EPY0001394 | Fusidic acid for peak identification | EP unit |
EPY0001395 | Voriconazole | EP unit |
EPY0001396 | Voriconazole impurity B - (2RS,3SR)-2-(2,4-difluorophenyl)-3-pyrimidin-4-yl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol | EP unit |
EPY0001397 | Voriconazole impurity E - [(1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid ((+-)-camphorsulfonic acid) | EP unit |
EPY0001398 | Voriconazole impurity D - (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (epi-voriconazole) | EP unit |
EPY0001399 | Fulvestrant | EP unit |
EPY0001400 | Vigabatrin | EP unit |
EPY0001401 | Vigabatrin impurity A - (5RS)-5-ethenylpyrrolidin-2-one | EP unit |
EPY0001402 | Vigabatrin impurity B - (2E)-2-(2-aminoethyl)but-2-enoic acid | EP unit |
EPY0001403 | Vigabatrin impurity E - 2-[(2RS)-2-aminobut-3-enyl]propanedioic acid | EP unit |
EPY0001404 | Vigabatrin impurity D - 4-aminobutanoic acid | EP unit |
EPY0001405 | Olmesartan medoxomil | EP unit |
EPY0001407 | Glucosamine sulfate sodium chloride | EP unit |
EPY0001408 | Prilocaine impurity B - 2-methylbenzenamine hydrochloride | EP unit |
EPY0001409 | Testosterone propionate for system suitability | EP unit |
EPY0001410 | Sodium fusidate | EP unit |
EPY0001411 | Fusidic acid | EP unit |
EPY0001413 | Fulvestrant for system sitability | EP unit |
EPY0001414 | Human Hepatitis B immunoglobulin | EP unit |
EPY0001416 | Betamethasone dipropionate for peak identification | EP unit |
EPY0001417 | Tadalafil | EP unit |
EPY0001418 | Betamethasne dipropionate for system suitability | EP unit |
EPY0001420 | Stanazol impurity B | EP unit |
EPY0001421 | Bifonazole for system suitability | EP unit |
EPY0001422 | Valproic acid for system suitability | EP unit |
EPY0001423 | Difloxacin hydrochloride | EP unit |
EPY0001424 | Olmesartan medoxomil for system suitability | EP unit |
EPY0001425 | Nicotine ditartrate dihydrate | EP unit |
EPY0001426 | Carvedilol for system suitability | EP unit |
EPY0001427 | Carvedilol (EP) | EP unit |
EPY0001428 | Pheniramine impurity A - 2-Benzylpyridine | EP unit |
EPY0001429 | Difloxacin impurity G - 7-chloro-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | EP unit |
EPY0001431 | Levonorgestrel for system suitability | EP unit |
EPY0001432 | Minoxidil for system suitability | EP unit |
EPY0001433 | Montelukast racemate | EP unit |
EPY0001434 | Montelukast sodium | EP unit |
EPY0001435 | Montelukast for peak identification | EP unit |
EPY0001437 | Nateglinide | EP unit |
EPY0001438 | Long pepper for system suitability | EP unit |
EPY0001439 | Diltiazem impurity F - (2S,3S)-5-[2-(dimethylamino)ethyl]-3-hydroxy-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one | EP unit |
EPY0001440 | Nateglinide impurity A - trans-4-(1-methylethyl)cyclohexanecarboxylic acid | EP unit |
EPY0001441 | Nateglinide impurity B - N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-Lphenylalanine (L-phenylalanine isomer) | EP unit |
EPY0001442 | Nateglinide impurity C - N-[[cis-4-(1-methylethyl)cyclohexyl]carbonyl]-D-phenylalanine (cis-isomer) | EP unit |
EPY0001444 | Bicalutamide | EP unit |
EPY0001445 | Celecoxib | EP unit |
EPY0001446 | Celecoxib impurity A - 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide | EP unit |
EPY0001447 | Celecoxib impurity B - 4-[3-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide | EP unit |
EPY0001448 | Bicalutamide for system suitability | EP unit |
EPY0001449 | Chlorpromazine impurity F - 3-(4-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine | EP unit |
EPY0001450 | Captopril impurity J - (2S)-1-[(2S)-3-(acetylsulfanyl)-2-methylpropanoyl]pyrrolidine-2-carboxylic acid (acetylcaptopril) | EP unit |
EPY0001451 | Chlortetracycline for system suitability | EP unit |
EPY0001452 | Docetaxel impurity E - 5beta,20-epoxy-4-(acetyloxy)-1,7beta,10beta,13-tetrahydroxy-9-oxotax-11-en-2-yl benzoate (10-desacetyl-baccatin III) | EP unit |
EPY0001453 | Duloxetine hydrochloride | EP unit |
EPY0001454 | Duloxetine for system suitability | EP unit |
EPY0001455 | Duloxetine impurity A - (3R)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine | EP unit |
EPY0001456 | Nitrendipine for peak identification | EP unit |
EPY0001457 | Melphalan for system suitability | EP unit |
EPY0001458 | Piretanide for system suitability | EP unit |
EPY0001459 | Triamcinolone acetonide for system suitability | EP unit |
EPY0001460 | Acetylsalicylic acid for peak identification (10.26 mg) | EP unit |
EPY0001461 | Amidotrizoic acid for system suitability | EP unit |
EPY0001462 | Acetylsulfadiazine | EP unit |
EPY0001463 | Actaea racemosa HRS | EP unit |
EPY0001464 | Actaea rasemosa dry extract for system suitability HRS | EP unit |
EPY0001465 | Apomorphine hydrochloride hemihydrate | EP unit |
EPY0001466 | Anhydrous Docetaxel | EP unit |
EPY0001467 | Amikacin impurity I - (2S)-4-amino-2-hydroxybutanoic acid | EP unit |
EPY0001468 | Sodium iodohippurate | EP unit |
EPY0001469 | Sulfadiazine impurity A - 2,6-dimethylaniline | EP unit |
EPY0001470 | Benzoic acid | EP unit |
EPY0001472 | Coagulation Factors V, VIII, XI and XIII plasma | EP unit |
EPY0001473 | Goserelin for NMR identification | EP unit |
EPY0001474 | Lauric acid | EP unit |